Table 3.
Administered vaccines against SARS-CoV-2.
| No. | % | |
|---|---|---|
| Entire cohort | 156 | 100 |
| Unvaccinated | 10 | 6.4 |
| Unknown vaccination status | 3 | 1.9 |
| Vaccinated/number of vaccinations | ||
| First vaccine | 143 | 91.7 |
| Vaxzevria® (AstraZeneca AB) | 12 | |
| Comirnaty® (BioNTech GmbH) | 114 | |
| Jcovden® (Johnson & Johnson) | 4 | |
| Spikevax® (Moderna Biotech) | 13 | |
| Second vaccine | 136 | 87.1 |
| Vaxzevria® | 4 | |
| Comirnaty® | 113 | |
| Spikevax® | 18 | |
| Unknown | 1 | |
| Third vaccine | 113 | 72.4 |
| Vaxzevria® | 3 | |
| Comirnaty® | 83 | |
| Spikevax® | 25 | |
| Unknown | 2 | |
| Fourth vaccine | 11 | 7.1 |
| Comirnaty® | 8 | |
| Spikevax® | 2 | |
| Unknown® | 1 |
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.